Device that uses light and sound may slow Alzheimer’s symptoms in some patients

Résumé détaillé
An experimental device that uses light and sound to stimulate the brain appeared to slow cognitive decline in people at early stages of Alzheimer’s disease, according to mixed…
An experimental device that uses light and sound to stimulate the brain appeared to slow cognitive decline in people at early stages of Alzheimer’s disease, according to clinical trial results announced Monday at a scientific conference in Boston.
Cognito Therapeutics, the Cambridge biotech company behind the device — which is non-invasive, can be used at home, and looks like a pair of sunglasses attached to headphones — said the findings hold promise for millions of people with the incurable illness.
The results, which have not yet been peer-reviewed, will be submitted to the New England Journal of Medicine, the company said.
“The potential implications are massive,” said Christian Howell, Cognito’s CEO. “Many people have the ability to bring this into their lives and really positively impact what they’re experiencing.”
The trial, which was designed to measure efficacy in people with mild to moderate Alzheimer’s, did not show a treatment effect in people with moderate cases, Howell said.
The invention, which is called Spectris, uses gamma wave therapy and is based on research by MIT scientists.
Gamma waves are electrical signals that brain cells make when people are learning or concentrating. Although neuroscientists have known that these signals are slower or missing in people with Alzheimer’s, it wasn’t until 2016 when researchers led by MIT neuroscientists Li-Huei Tsai and Ed Boyden first discovered that the brainwaves had the potential to be a therapy.
The MIT researchers learned they could trigger gamma waves in mice using simple light and sound stimulation. They observed that the brainwaves could clear mouse brains of sticky clumps of proteins called amyloid plaques, known to accumulate in the brains of Alzheimer’s patients. Tsai and Boyden went on to co-found Cognito and remain as scientific advisors to the company.
The technology, Howell noted, does not clear amyloid plaques or tau, another brain protein associated with Alzheimer’s, from people.
Début de l'article, extrait de The Boston Globe. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.bostonglobe.com)



